Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:IDYA NASDAQ:MNPR OTCMKTS:NWPHF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AIDYAIDEAYA Biosciences$28.98+0.5%$29.89$20.50▼$39.28$2.53B-0.051.06 million shs617,100 shsMNPRMonopar Therapeutics$59.77+1.1%$58.71$29.18▼$105.00$395.88M1.52143,846 shs154,407 shsNWPHFNewron Pharmaceuticals$20.00$20.00$9.10▼$20.00$37.49M0.53600 shsN/A7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences+0.49%+2.44%+0.28%-12.42%+32.21%MNPRMonopar Therapeutics+1.13%+0.49%-2.72%-0.98%+72.50%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%+113.68%+113.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46N/AN/AN/AN/AIDYAIDEAYA Biosciences$28.98+0.5%$29.89$20.50▼$39.28$2.53B-0.051.06 million shs617,100 shsMNPRMonopar Therapeutics$59.77+1.1%$58.71$29.18▼$105.00$395.88M1.52143,846 shs154,407 shsNWPHFNewron Pharmaceuticals$20.00$20.00$9.10▼$20.00$37.49M0.53600 shsN/A7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%IDYAIDEAYA Biosciences+0.49%+2.44%+0.28%-12.42%+32.21%MNPRMonopar Therapeutics+1.13%+0.49%-2.72%-0.98%+72.50%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%+113.68%+113.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/AIDYAIDEAYA Biosciences 2.82Moderate Buy$50.6974.91% UpsideMNPRMonopar Therapeutics 3.00Buy$107.9180.54% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NWPHF, ARAV, MNPR, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.006/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026IDYAIDEAYA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/2/2026IDYAIDEAYA Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$58.005/22/2026IDYAIDEAYA Biosciences Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/7/2026IDYAIDEAYA Biosciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$52.00 ➝ $50.004/21/2026IDYAIDEAYA Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026IDYAIDEAYA Biosciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$49.00 ➝ $53.004/14/2026IDYAIDEAYA Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$31.00 ➝ $35.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAraviveN/AN/AN/AN/AN/AN/AIDYAIDEAYA Biosciences$218.71M11.64N/AN/A$11.67 per share2.48MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ANWPHFNewron Pharmaceuticals$6.82M52.35N/AN/A$0.21 per share95.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAraviveN/A-$0.90N/AN/AN/AN/AN/AN/AN/AIDYAIDEAYA Biosciences-$113.70M-$1.60N/AN/AN/AN/A-14.24%-13.09%8/4/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/AN/AN/AN/AN/AN/AN/AN/ALatest NWPHF, ARAV, MNPR, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/5/2026Q1 2026IDYAIDEAYA Biosciences-$1.07-$1.11-$0.04-$1.11$5.04 million$6.56 million3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/AIDYAIDEAYA BiosciencesN/A10.7410.74MNPRMonopar TherapeuticsN/A56.0456.04NWPHFNewron PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%IDYAIDEAYA Biosciences98.29%MNPRMonopar Therapeutics1.83%NWPHFNewron PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipARAVAravive60.40%IDYAIDEAYA Biosciences4.70%MNPRMonopar Therapeutics20.50%NWPHFNewron PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive20N/AN/ANo DataIDYAIDEAYA Biosciences8087.86 million83.73 millionOptionableMNPRMonopar Therapeutics106.70 million5.33 millionNot OptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableNWPHF, ARAV, MNPR, and IDYA HeadlinesRecent News About These CompaniesNewron Pharmaceuticals to Participate in June Investor ConferencesMay 28, 2026 | businesswire.comNewron announces US FDA has placed a hold on enrollment of new patients in US sites of its ENIGMA-TRS 2 study of evenamideMay 2, 2026 | pharmabiz.comPPatient death prompts FDA pause on Newron’s Phase 3 schizophrenia studyApril 30, 2026 | biospace.comBPatient death puts Newron’s late-stage schizophrenia trial on iceApril 30, 2026 | yahoo.comNewron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 StudyApril 29, 2026 | finance.yahoo.comFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient deathApril 29, 2026 | fiercebiotech.comFNewron Announces AGM 2026 ResultsApril 23, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Just Slashed This Year's EstimatesMarch 29, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMarch 27, 2026 | finance.yahoo.comNewron Pharmaceuticals S.p.A. (NWPHF) Q4 2025 Earnings Call TranscriptMarch 24, 2026 | seekingalpha.comEQS-News: Newron presents 2025 financial results and provides 2026 outlookMarch 24, 2026 | sharewise.comSNewron Presents 2025 Financial Results and Provides 2026 OutlookMarch 24, 2026 | finance.yahoo.comNewron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)March 20, 2026 | businesswire.comNewron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance ContractMarch 19, 2026 | pharmiweb.comPNewron Announces Nominations to Its Board of Directors at Upcoming Annual General MeetingMarch 18, 2026 | tmcnet.comNewron Secures Funding to Advance Key Schizophrenia DrugMarch 17, 2026 | newscase.comNNewron secures up to EUR 38 million to advance its ENIGMA-TRS pivotal phase III programmeFebruary 18, 2026 | pharmabiz.comPNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug EvenamideFebruary 17, 2026 | theglobeandmail.comNewron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia DrugFebruary 17, 2026 | theglobeandmail.comNewron secures up to 38 million euros to advance evenamide programFebruary 17, 2026 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWPHF, ARAV, MNPR, and IDYA Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 06/12/2026Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.IDEAYA Biosciences NASDAQ:IDYA$28.98 +0.14 (+0.49%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$29.38 +0.40 (+1.38%) As of 06/12/2026 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Monopar Therapeutics NASDAQ:MNPR$59.77 +0.67 (+1.13%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$59.68 -0.09 (-0.15%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Newron Pharmaceuticals OTCMKTS:NWPHF$20.00 0.00 (0.00%) As of 06/12/2026Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
